IN2014DN07853A - - Google Patents

Info

Publication number
IN2014DN07853A
IN2014DN07853A IN7853DEN2014A IN2014DN07853A IN 2014DN07853 A IN2014DN07853 A IN 2014DN07853A IN 7853DEN2014 A IN7853DEN2014 A IN 7853DEN2014A IN 2014DN07853 A IN2014DN07853 A IN 2014DN07853A
Authority
IN
India
Prior art keywords
endonuclease
globin gene
disrupt
bell
fusion protein
Prior art date
Application number
Inventor
Michael A Bender
Mark T Groudine
Barry L Stoddard
Ryo Takeuchi
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of IN2014DN07853A publication Critical patent/IN2014DN07853A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases RNAses, DNAses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Abstract

Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s) including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bell la coding region; (b) to disrupt a Bell la gene regulatory region; (c) to modify an adult human ß-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway such as a Bell la regulated HbF silencing region; (e) to mutate one or more γ-globin gene promoter(s) to achieve increased expression of a γ-globin gene; (f) to mutate one or more δ-globin gene promoter(s) to achieve increased expression of a δ-globin gene; and/or (g) to correct one or more ß-globin gene mutation(s).
IN7853DEN2014 2012-02-24 2013-02-22 IN2014DN07853A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603231P 2012-02-24 2012-02-24
PCT/US2013/027459 WO2013126794A1 (en) 2012-02-24 2013-02-22 Compositions and methods for the treatment of hemoglobinopathies

Publications (1)

Publication Number Publication Date
IN2014DN07853A true IN2014DN07853A (en) 2015-04-24

Family

ID=49006265

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7853DEN2014 IN2014DN07853A (en) 2012-02-24 2013-02-22

Country Status (18)

Country Link
US (2) US20150166969A1 (en)
EP (2) EP2836226B1 (en)
JP (2) JP6170080B2 (en)
KR (2) KR101833589B1 (en)
CN (1) CN104284669A (en)
AU (2) AU2013222170B2 (en)
BR (1) BR112014020625A2 (en)
CA (1) CA2865129A1 (en)
DK (1) DK2836226T3 (en)
ES (1) ES2641840T3 (en)
HK (1) HK1249861A1 (en)
IL (2) IL234225B (en)
IN (1) IN2014DN07853A (en)
NZ (1) NZ630900A (en)
RU (2) RU2650811C2 (en)
SG (2) SG10201606959PA (en)
WO (1) WO2013126794A1 (en)
ZA (1) ZA201406187B (en)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
KR101833589B1 (en) 2012-02-24 2018-03-02 프레드 헛친슨 켄서 리서치 센터 Compositions and methods for the treatment of hemoglobinopathies
PT3241902T (en) 2012-05-25 2018-05-28 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CA2882499C (en) 2012-08-29 2023-09-26 Sangamo Biosciences, Inc. Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto
JP6542124B2 (en) 2012-11-27 2019-07-10 ザ チルドレンズ メディカル センター コーポレーション Targeting of the BCL11A distal regulatory element for reinduction of fetal hemoglobin
EP3138909A1 (en) 2012-12-06 2017-03-08 Sigma-Aldrich Co. LLC Crispr-based genome modification and regulation
US20140179770A1 (en) 2012-12-12 2014-06-26 Massachusetts Institute Of Technology Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014099744A1 (en) 2012-12-17 2014-06-26 President And Fellows Of Harvard College Rna-guided human genome engineering
US10138509B2 (en) 2013-03-12 2018-11-27 President And Fellows Of Harvard College Method for generating a three-dimensional nucleic acid containing matrix
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US10119133B2 (en) 2013-03-15 2018-11-06 The General Hospital Corporation Using truncated guide RNAs (tru-gRNAs) to increase specificity for RNA-guided genome editing
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
WO2014186585A2 (en) * 2013-05-15 2014-11-20 Sangamo Biosciences, Inc. Methods and compositions for treatment of a genetic condition
US9267135B2 (en) 2013-06-04 2016-02-23 President And Fellows Of Harvard College RNA-guided transcriptional regulation
CN114015726A (en) 2013-06-17 2022-02-08 布罗德研究所有限公司 Delivery, use and therapeutic applications of CRISPR-CAS systems and compositions for targeting disorders and diseases with viral components
MX2015017311A (en) 2013-06-17 2017-04-10 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells.
BR112015031608A2 (en) 2013-06-17 2017-08-22 Massachusetts Inst Technology APPLICATION AND USE OF CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR LIVER TARGETING AND THERAPY
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
WO2015006498A2 (en) * 2013-07-09 2015-01-15 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
WO2015006294A2 (en) 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
US11306328B2 (en) 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
ES2670983T3 (en) 2013-11-07 2018-06-04 Editas Medicine, Inc. Methods and compositions related to CRISPR with rRNA guiding
RS58671B1 (en) 2013-11-13 2019-06-28 Childrens Medical Center Nuclease-mediated regulation of gene expression
JP2016537028A (en) * 2013-11-18 2016-12-01 クリスパー セラピューティクス アーゲー CRISPR-CAS System Materials and Methods
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
US9074199B1 (en) 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
WO2015089419A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
AU2014361781B2 (en) 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
EP3089989B1 (en) * 2013-12-31 2020-06-24 The Regents of The University of California Cas9 crystals and methods of use thereof
CN106133141B (en) * 2014-01-08 2021-08-20 哈佛学院董事及会员团体 RNA-guided gene driving
CN113215219A (en) 2014-02-13 2021-08-06 宝生物工程(美国) 有限公司 Methods of depleting target molecules from an initial collection of nucleic acids, and compositions and kits for practicing same
WO2015138510A1 (en) 2014-03-10 2015-09-17 Editas Medicine., Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015148860A1 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta-thalassemia
WO2015148863A2 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
CN112063586A (en) * 2014-03-26 2020-12-11 布里格姆及妇女医院股份有限公司 Compositions and methods for ex vivo expansion of human hematopoietic stem/progenitor cells
EP3134130B1 (en) 2014-04-25 2019-06-12 Children's Medical Center Corporation Compositions and methods to treating hemoglobinopathies
EP4079847A1 (en) 2014-07-30 2022-10-26 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016025759A1 (en) * 2014-08-14 2016-02-18 Shen Yuelei Dna knock-in system
MX2017002935A (en) 2014-09-07 2017-05-30 Selecta Biosciences Inc Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses.
PT3194570T (en) * 2014-09-16 2021-08-06 Sangamo Therapeutics Inc Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US10370673B2 (en) 2014-09-26 2019-08-06 Purecircle Sdn Bhd Single nucleotide polymorphism (SNP) markers for stevia
KR102629128B1 (en) 2014-12-03 2024-01-25 애질런트 테크놀로지스, 인크. Guide rna with chemical modifications
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3237615B2 (en) 2014-12-24 2023-07-26 The Broad Institute, Inc. Crispr having or associated with destabilization domains
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
CN107429230B (en) 2015-01-26 2021-11-12 菲特治疗公司 Methods and compositions for inducing hematopoietic cell differentiation
WO2016135559A2 (en) * 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
AU2016225178B2 (en) * 2015-02-23 2022-05-05 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
AU2016246450B2 (en) 2015-04-06 2022-03-17 Agilent Technologies, Inc. Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation
US10155938B2 (en) * 2015-04-14 2018-12-18 City Of Hope Coexpression of CAS9 and TREX2 for targeted mutagenesis
CN104805118A (en) * 2015-04-22 2015-07-29 扬州大学 Method for targeted knockout of specific gene of Suqin yellow chicken embryonic stem cell
US11845928B2 (en) * 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
EP3294873B1 (en) * 2015-05-08 2020-08-19 The Children's Medical Center Corporation Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
EP3307887A1 (en) 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
CA2989858A1 (en) 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
US11643668B2 (en) 2015-06-17 2023-05-09 The Uab Research Foundation CRISPR/Cas9 complex for genomic editing
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CN108350449B (en) 2015-08-28 2022-05-31 通用医疗公司 Engineered CRISPR-Cas9 nuclease
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9897378B2 (en) 2015-10-08 2018-02-20 Nyc Designed Inspirations Llc Cosmetic makeup sponge/blender container
CN108513575A (en) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 Nucleobase editing machine and application thereof
US20180325947A1 (en) * 2015-10-27 2018-11-15 Children's Hospital Medical Center Use of mapk inhibitors to reduce loss of hematopoietic stem cells during ex vivo culture and/or genetic manipulation
MX2018005611A (en) 2015-11-03 2018-11-09 Harvard College Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix.
US20180273609A1 (en) * 2015-11-04 2018-09-27 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
EP4249074A3 (en) 2015-11-04 2024-01-10 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
EP3371301A4 (en) 2015-11-04 2019-06-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
IL308706A (en) * 2015-12-28 2024-01-01 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
PT3408382T (en) 2016-01-27 2022-06-27 Oncorus Inc Oncolytic viral vectors and uses thereof
US11530253B2 (en) 2016-02-25 2022-12-20 The Children's Medical Center Corporation Customized class switch of immunoglobulin genes in lymphoma and hybridoma by CRISPR/CAS9 technology
US20200255857A1 (en) * 2016-03-14 2020-08-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
EP3445388A2 (en) * 2016-04-18 2019-02-27 CRISPR Therapeutics AG Materials and methods for treatment of hemoglobinopathies
WO2017189525A1 (en) 2016-04-25 2017-11-02 President And Fellows Of Harvard College Hybridization chain reaction methods for in situ molecular detection
WO2017191503A1 (en) * 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CA3031785A1 (en) * 2016-07-25 2018-02-01 Bluebird Bio, Inc. Bcl11a homing endonuclease variants, compositions, and methods of use
KR20230095129A (en) 2016-08-03 2023-06-28 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Adenosine nucleobase editors and uses thereof
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
EP3497214B1 (en) 2016-08-09 2023-06-28 President and Fellows of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
CN106244555A (en) * 2016-08-23 2016-12-21 广州医科大学附属第三医院 A kind of method of efficiency improving gene targeting and the base in-situ remediation method in beta globin gene site
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
EP4248979A3 (en) * 2016-09-08 2023-12-20 2seventy bio, Inc. Pd-1 homing endonuclease variants, compositions, and methods of use
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
AU2018212854A1 (en) 2017-01-27 2019-08-01 Children's Hospital Medical Center Methods of enhancing engraftment activity of hematopoietic stem cells
TW201839136A (en) * 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (en) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
WO2018195545A2 (en) 2017-04-21 2018-10-25 The General Hospital Corporation Variants of cpf1 (cas12a) with altered pam specificity
EP3615664A4 (en) * 2017-04-24 2021-01-27 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Homology directed repair compositions for the treatment of hemoglobinopathies
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
WO2018218166A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Using split deaminases to limit unwanted off-target base editor deamination
WO2018220210A1 (en) * 2017-06-02 2018-12-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
AU2018306455A1 (en) 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
WO2019070974A1 (en) 2017-10-04 2019-04-11 Bluebird Bio, Inc. Pcsk9 endonuclease variants, compositions, and methods of use
KR20200086670A (en) 2017-10-13 2020-07-17 셀렉타 바이오사이언시즈, 인크. Methods and compositions for attenuating antiviral delivery vector IgM responses
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US20210180091A1 (en) * 2017-10-26 2021-06-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
CN109722415B (en) * 2017-10-27 2021-01-26 博雅辑因(北京)生物科技有限公司 Hematopoietic stem cell culture composition, culture medium and hematopoietic stem cell culture method
WO2019113149A1 (en) * 2017-12-05 2019-06-13 Crispr Therapeutics Ag Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
EP3749767A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3749768A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
AU2019260754A1 (en) * 2018-04-27 2020-11-26 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase
US20200102563A1 (en) * 2018-10-02 2020-04-02 Exosome Therapeutics, Inc. Exosome loaded therapeutics for treating sickle cell disease
KR20210102925A (en) * 2018-12-10 2021-08-20 블루버드 바이오, 인코포레이티드. Homing Endonuclease Variants
EP3898958A1 (en) 2018-12-17 2021-10-27 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US11946040B2 (en) 2019-02-04 2024-04-02 The General Hospital Corporation Adenine DNA base editor variants with reduced off-target RNA editing
CA3128755A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020191249A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
CN110042124A (en) * 2019-04-25 2019-07-23 国家卫生健康委科学技术研究所 Genome base editor increases the kit of fetal hemoglobin level and application in human red blood cells
CN111939271A (en) * 2019-04-30 2020-11-17 博雅辑因(北京)生物科技有限公司 Method for predicting treatment effectiveness of hemoglobinopathy
EA202192931A1 (en) * 2019-04-30 2022-02-22 Эдиджен Инк. METHOD FOR PREDICTION OF THE EFFICIENCY OF HEMOGLOBINOPATHY TREATMENT
AU2020284555A1 (en) 2019-05-28 2021-12-23 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CN114072518A (en) * 2019-06-28 2022-02-18 Asc治疗公司 Methods and compositions for treating thalassemia or sickle cell disease
AU2020358863A1 (en) 2019-10-03 2022-05-12 Artisan Development Labs, Inc. CRISPR systems with engineered dual guide nucleic acids
EP4058586A4 (en) * 2019-11-15 2024-04-10 Univ Leland Stanford Junior Targeted integration at alpha-globin locus in human hematopoietic stem and progenitor cells
CN112979823B (en) * 2019-12-18 2022-04-08 华东师范大学 Product and fusion protein for treating and/or preventing beta-hemoglobinopathy
DE112021002672T5 (en) 2020-05-08 2023-04-13 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
EP4150081A1 (en) * 2020-05-13 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Base editing approaches for the treatment of betahemoglobinopathies
EP4262850A1 (en) * 2020-12-21 2023-10-25 2seventy bio, Inc. Compositions and methods for site-directed mutagenesis
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
CN113481184A (en) * 2021-08-06 2021-10-08 北京大学 Fusion proteins and methods of use thereof
CA3230927A1 (en) 2021-09-10 2023-03-16 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
CN114457119B (en) * 2022-04-11 2022-08-12 中吉智药(南京)生物技术有限公司 Application of lentiviral vector in preparation of drug for treating beta-thalassemia
EP4273242A1 (en) * 2022-05-03 2023-11-08 ETH Zurich Crispr-based modification of human hbd gene

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182673A1 (en) * 1998-05-15 2002-12-05 Genentech, Inc. IL-17 homologous polypedies and therapeutic uses thereof
EP1590453B1 (en) 2003-01-28 2013-11-27 Cellectis Custom-made meganuclease and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2008010009A1 (en) 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
CA2678526A1 (en) 2007-02-19 2008-08-28 Cellectis Laglidadg homing endonuclease variants having novel substrate specificity and use thereof
WO2009013559A1 (en) * 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
US8383604B2 (en) * 2008-09-15 2013-02-26 Children's Medical Center Corporation Modulation of BCL11A for treatment of hemoglobinopathies
US20140148361A1 (en) 2010-06-07 2014-05-29 Barry L. Stoddard Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof
EP2680877B1 (en) * 2011-02-28 2019-07-10 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption
KR101833589B1 (en) 2012-02-24 2018-03-02 프레드 헛친슨 켄서 리서치 센터 Compositions and methods for the treatment of hemoglobinopathies
CA2882499C (en) * 2012-08-29 2023-09-26 Sangamo Biosciences, Inc. Cells genetically modified within the bcl11a gene by a nuclease and various aspects related thereto

Also Published As

Publication number Publication date
AU2017201235A1 (en) 2017-03-16
WO2013126794A1 (en) 2013-08-29
EP3272356A1 (en) 2018-01-24
AU2013222170A1 (en) 2014-10-02
SG11201405103SA (en) 2014-09-26
BR112014020625A2 (en) 2017-07-04
US20150166969A1 (en) 2015-06-18
AU2017201235B2 (en) 2018-08-02
EP2836226A1 (en) 2015-02-18
CA2865129A1 (en) 2013-08-29
ES2641840T3 (en) 2017-11-14
RU2650811C2 (en) 2018-04-17
EP2836226A4 (en) 2016-04-13
RU2018109507A (en) 2019-02-28
KR20140128453A (en) 2014-11-05
HK1249861A1 (en) 2018-11-16
IL234225B (en) 2019-05-30
US10619140B2 (en) 2020-04-14
ZA201406187B (en) 2018-05-30
DK2836226T3 (en) 2017-09-18
CN104284669A (en) 2015-01-14
EP2836226B1 (en) 2017-06-28
US20170298329A1 (en) 2017-10-19
JP6170080B2 (en) 2017-07-26
AU2013222170B2 (en) 2017-01-05
JP2017148056A (en) 2017-08-31
JP2015516146A (en) 2015-06-11
IL266582A (en) 2019-07-31
KR20180009383A (en) 2018-01-26
AU2017201235C1 (en) 2018-11-01
SG10201606959PA (en) 2016-09-29
NZ630900A (en) 2016-10-28
RU2014138491A (en) 2016-04-10
KR101833589B1 (en) 2018-03-02

Similar Documents

Publication Publication Date Title
IN2014DN07853A (en)
BR112017017812A2 (en) Materials and methods for treatment of hemoglobinopathies
MX2022000378A (en) METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs.
MX2018008733A (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process.
WO2016135559A3 (en) Materials and methods for treatment of human genetic diseases including hemoglobinopathies
MX2016013832A (en) Compositions and methods to treating hemoglobinopathies.
MX2015006528A (en) Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction.
MY172726A (en) Humanized il-6 and il-6 receptor
MX2018011791A (en) Compounds for improved viral transduction.
IN2014DN00288A (en)
IN2014DN00286A (en)
IN2014MN00093A (en)
IN2014MN01378A (en)
MX2016001204A (en) Adeno-associated viral (aav) vectors useful for trasducing adipose tissue.
WO2014074852A8 (en) Compositions and methods for modulating an immune response
WO2014143884A3 (en) Synthetic methylmalonyl-coa mutase transgene for the treatment of mut class methylmalonic acidemia (mma)
WO2012087676A3 (en) Production of fatty acids and fatty acid derivatives by recombinant microorganisms
NZ726355A (en) Humanized dipeptidyl peptidase iv (dpp4) animals
WO2014026110A3 (en) Compounds for improved viral transduction
MX350445B (en) Complement factor b analogs and their uses.
AR092152A1 (en) USE OF A CORN TRANSLATED REGION FOR TRANSGENIC EXPRESSION IN PLANTS
MX357166B (en) Antibodies to notum pectinacetylesterase.
MX2010008942A (en) Anti-tumour effective paramyxovirus.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
MX2016015574A (en) Purified compositions of ivig and kh proteins for modulating lymphocytes and treating hepatitis b virus.